CYC682: Interim Phase I data

Interim data from a U.S. Phase I trial in 18 patients showed that CYC682 led to stable disease in 1 ovarian cancer patient, 1 unknown primary-peritoneal carcinomatosis patient and 4 non-small cell lun...